+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Vulvovaginal Candidiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • TechSci Research
  • ID: 5755440
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Vulvovaginal Candidiasis Treatment Market was valued at USD 0.98 Billion in 2024, and is expected to reach USD 1.28 Billion by 2030, rising at a CAGR of 4.52%. The global market for Vulvovaginal Candidiasis Treatment is experiencing significant growth, driven by the growing development of new antifungal drugs and growing healthcare expenditure across the globe.

Additionally, growing demand for the best treatment with low cost, along with growing geriatric population have significantly increased the demand for vulvovaginal candidiasis treatment across different parts of the globe. Additionally, increasing prevalence of chronic diseases like cancer, cardiovascular diseases, neurological diseases, and diabetes across the globe is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby fuelling the market growth. Besides, growing awareness on maintaining hygiene and benefits of using new treatments with lower cost is further expected to support the vulvovaginal candidiasis treatment market during the forecast period.

Furthermore, increasing usage of broad-spectrum antibiotic such as Fluconazole because of yeast infection is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby supporting the market growth. It is the second most common type of vaginal infection after bacterial vaginal infections, in the United States. An estimated 1.4 million outpatient visits for vaginal candidiasis occur annually.

Key Market Drivers

Rising Prevalence of Vulvovaginal Candidiasis and Recurrent Infections

One of the primary drivers of growth in the global VVC treatment market is the rising prevalence of both acute and recurrent vulvovaginal candidiasis infections. Vulvovaginal candidiasis is caused predominantly by Candida albicans, and affects a large proportion of women worldwide, especially those of reproductive age. According to the Centers for Disease Control and Prevention (CDC), approximately 75% of all women will experience at least one episode of VVC during their lifetime, and nearly 40-45% of these individuals will experience two or more episodes.

Around 5-8% of women are affected by recurrent vulvovaginal candidiasis (RVVC), which is defined as four or more symptomatic episodes within a year. Several factors contribute to this high prevalence: increased antibiotic use, hormonal changes (due to pregnancy or contraceptives), diabetes, immunosuppression (including HIV/AIDS), and the growing use of immunosuppressive medications. The World Health Organization (WHO) notes that nearly 37.7 million people globally were living with HIV as of 2023, a key risk factor for fungal infections such as VVC.

The growing global awareness surrounding women's reproductive health, increased healthcare access, and proactive screening campaigns are further driving diagnosis rates, prompting a higher demand for effective antifungal therapies. Moreover, the global emphasis on sexual health and infection control, particularly in developing regions, has led to increased funding and outreach efforts aimed at early detection and treatment of fungal infections. Collectively, these trends underscore a growing need for both over the counter (OTC) and prescription treatments, fueling market expansion.

Key Market Challenges

Antifungal Resistance and Limited Treatment Efficacy

A significant challenge to the VVC treatment market is the increasing resistance to conventional antifungal drugs, particularly azoles. Repeated and often inappropriate use of azole antifungals such as fluconazole has led to decreased efficacy in many patients, especially those with recurrent vulvovaginal candidiasis (RVVC). Drug-resistant Candida species, including Candida glabrata and Candida auris, are becoming more prevalent and are often harder to treat. The World Health Organization (WHO), in its 2023 publication on fungal priority pathogens, classified Candida auris as a critical priority pathogen due to its high resistance profile, global spread, and association with severe healthcare outbreaks. The WHO has also recognized the urgent need for new antifungal drug development to address growing treatment gaps and antimicrobial resistance (AMR).

Furthermore, research by the Centers for Disease Control and Prevention (CDC) reveals that fluconazole resistance among Candida strains has increased steadily in recent years, complicating treatment decisions for physicians and leading to higher rates of treatment failure. This resistance is compounded by patient non-compliance, self-medication, and lack of definitive diagnostics, especially in low-resource settings. Addressing antifungal resistance requires substantial investment in surveillance, diagnostics, and antimicrobial stewardship programs. However, in many countries, such efforts remain underfunded or fragmented, hindering the timely management of resistant infections and posing a long-term threat to treatment efficacy and patient outcomes.

Key Market Trends

Shift Toward Novel and Non-Azole Antifungal Therapies

A significant trend in the VVC treatment market is the development and growing preference for non-azole antifungal therapies, particularly in cases of recurrent or drug-resistant infections. Traditional azole-based medications (like fluconazole, clotrimazole, and miconazole) have long been the mainstay for treating VVC. However, emerging drug resistance and the limited efficacy of azoles in recurrent infections have necessitated the development of novel antifungal agents. The shift is supported by increased research and regulatory momentum. For instance, the U.S. FDA approved ibrexafungerp, a novel triterpenoid antifungal agent, for the treatment of VVC in 2021. This new class of antifungals works differently from azoles, targeting the fungal cell wall rather than its membrane, offering a promising alternative for patients with azole-resistant candidiasis or intolerance to existing medications.

Government research institutions and funding agencies are also prioritizing antimicrobial resistance (AMR) and fungal infections. The CDC’s Antibiotic Resistance Threats Report (2023) includes Candida species as serious threats, especially Candida auris, which is resistant to multiple antifungal drugs. As part of its response, the U.S. government is supporting antifungal drug development under initiatives such as the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB). This trend is likely to grow stronger as more patients and physicians seek effective treatment options for recurrent infections. Moreover, the pharmaceutical industry is investing in oral and topical agents that offer better bioavailability, fewer side effects, and resistance management - driving innovation in the market landscape.

Key Market Players

  • Astellas Pharma Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Basilea Pharmaceutica Ltd.
  • Scynexis, Inc.
  • Grupo Ferrer Internacional, S.A.
  • Pfizer, Inc.
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc.
  • Cidara Therapeutics, Inc.
  • Amplyx Pharmaceuticals Inc.

Report Scope:

In this report, the Global Vulvovaginal Candidiasis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vulvovaginal Candidiasis Treatment Market, By Drug Class:

  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others

Vulvovaginal Candidiasis Treatment Market, By Route of Administration:

  • Oral
  • Intravenous
  • Topical

Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Vulvovaginal Candidiasis Treatment Market, By Region:

  • North America
  • United States
  • Mexico
  • Canada
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vulvovaginal Candidiasis Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Vulvovaginal Candidiasis Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others)
6.2.2. By Route of Administration (Oral, Intravenous, Topical)
6.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
6.2.4. By Region
6.2.5. By Company (2024)
6.3. Market Map
6.3.1. By Drug Class
6.3.2. By Route of Administration
6.3.3. By Distribution Channel
6.3.4. By Region
7. North America Vulvovaginal Candidiasis Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Vulvovaginal Candidiasis Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. Canada Vulvovaginal Candidiasis Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. Mexico Vulvovaginal Candidiasis Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
8. Europe Vulvovaginal Candidiasis Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Vulvovaginal Candidiasis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. Germany Vulvovaginal Candidiasis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. United Kingdom Vulvovaginal Candidiasis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. Italy Vulvovaginal Candidiasis Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Spain Vulvovaginal Candidiasis Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. Asia-Pacific Vulvovaginal Candidiasis Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Vulvovaginal Candidiasis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. India Vulvovaginal Candidiasis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. Japan Vulvovaginal Candidiasis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
9.3.4. South Korea Vulvovaginal Candidiasis Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Class
9.3.4.2.2. By Route of Administration
9.3.4.2.3. By Distribution Channel
9.3.5. Australia Vulvovaginal Candidiasis Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Drug Class
9.3.5.2.2. By Route of Administration
9.3.5.2.3. By Distribution Channel
10. South America Vulvovaginal Candidiasis Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Vulvovaginal Candidiasis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Argentina Vulvovaginal Candidiasis Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Colombia Vulvovaginal Candidiasis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Class
11.2.2. By Route of Administration
11.2.3. By Distribution Channel
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Vulvovaginal Candidiasis Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Class
11.3.1.2.2. By Route of Administration
11.3.1.2.3. By Distribution Channel
11.3.2. Saudi Arabia Vulvovaginal Candidiasis Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Class
11.3.2.2.2. By Route of Administration
11.3.2.2.3. By Distribution Channel
11.3.3. UAE Vulvovaginal Candidiasis Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Class
11.3.3.2.2. By Route of Administration
11.3.3.2.3. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Porters Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products/Services
15. SWOT Analysis: Global Vulvovaginal Candidiasis Treatment Market
16. Competitive Landscape
16.1. Astellas Pharma Inc.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (As Reported)
16.1.5. Recent Developments
16.1.6. Key Personnel Details
16.1.7. SWOT Analysis
16.2. Mycovia Pharmaceuticals, Inc.
16.3. Basilea Pharmaceutica Ltd.
16.4. Scynexis, Inc.
16.5. Grupo Ferrer Internacional, S.A.
16.6. Pfizer, Inc.
16.7. Pacgen Life Science Corporation
16.8. NovaDigm Therapeutics, Inc.
16.9. Cidara Therapeutics, Inc.
16.10. Amplyx Pharmaceuticals Inc.
17. Strategic Recommendations18. About the Publisher & Disclaimer

Companies Mentioned

  • Astellas Pharma Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Basilea Pharmaceutica Ltd.
  • Scynexis, Inc.
  • Grupo Ferrer Internacional, S.A.
  • Pfizer, Inc.
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc.
  • Cidara Therapeutics, Inc.
  • Amplyx Pharmaceuticals Inc.

Table Information